Novo Nordisk A/S agreed to collaborate with Orbis Medicines ApS on next-generation pills for heart and metabolic diseases in a deal worth as much as $1.4 billion, according to Bloomberg.
Article
Novo Nordisk Signs Up to $1.4 Billion Drug Pact With Orbis
--・
Avertissement : ce contenu inclut des opinions de tiers. Il ne constitue pas un conseil. Binance Ai peut être utilisée, sans garantie de résultat. Consultez les CG.